Minireviews
Copyright ©The Author(s) 2016.
World J Gastrointest Pathophysiol. Feb 15, 2016; 7(1): 117-124
Published online Feb 15, 2016. doi: 10.4291/wjgp.v7.i1.117
Table 1 Duodenal neuroendocrine tumors treatment
Duodenal NETs – surgical treatment
≤ 1 cmLocal ressection (if possible)
≥ 2 cm OR lymph nodes metastasisSurgical ressection
Potentially resectable hepatic metastases without distant metastases and no other significant comorbilityPalliative surgery
Duodenal NETs – farmacological treatment
Functional duodenal NETsHormone suppression treatment
Well-differentiated NETsSystemic chemotherapy if advanced metastatic disease
Poorly differentiated tumorsCombination chemotherapy – variable duration disease remission
mTOR, tyrosine kinase and VEGF inhibitors – phase 3 trials with promising results
Metastatic or inoperable diseasePeptide receptor radionuclide therapy
When all other treatment options fail
If positive octreoscan
Table 2 Jejunal and ileal neuroendocrine tumors treatment
Jejunal and ileal NETs – surgical treatment
Without metastasis, all sizesSurgical resection with wide lymphadenectomy + search for other lesions
With liver metastasesAttempt curative surgery; intraoperative ultrasonography should be performed for detection of all liver metastases
If patient not suitable for curative resection, palliative surgery should be considered to prevent complications attributable to the tumor mass
Jejunal and ileal NETs – farmacological treatment
Functional jejunal-ileal NETs1st line: Somatostatin analogs (symptomatic treatment and tumor growth stabilization)
2nd line: Interferon-α
Well-differentiated NETsSystemic chemotherapy not recommended
Poorly differentiated tumorsCombination chemotherapy – variable duration disease remission
mTOR, tyrosine kinase and VEGF inhibitors – phase 3 trials with promising results
Metastatic or inoperable diseasePeptide receptor radionuclide therapy
When all other treatment options fail
If positive Octreoscan